Cost-effectiveness of lung MRI in lung cancer screening.
Bradley D AllenMark L SchieblerGregor SommerHans-Ulrich KauczorJuergen BiedererTimothy J KruserJames C CarrGordon HazenPublished in: European radiology (2019)
• In this Markov model of lung cancer screening, there is no difference in mortality between yearly screening with MRI and low-dose CT. • Compared to low-dose CT, screening with MRI led to a reduction in false-positive studies from 26 to 2.8% in men and 26 to 2.6% in women. • Due to similar life-expectancy and reduced false-positive rate, we found a favorable cost-effectiveness ratio of $258,169 in men and $403,888 in women of MRI relative to low-dose CT.
Keyphrases
- contrast enhanced
- low dose
- magnetic resonance imaging
- computed tomography
- magnetic resonance
- diffusion weighted imaging
- high dose
- image quality
- dual energy
- polycystic ovary syndrome
- positron emission tomography
- cardiovascular disease
- cardiovascular events
- pregnancy outcomes
- middle aged
- pregnant women
- metabolic syndrome
- coronary artery disease
- case control
- pet ct